Profile
Sector:
HealthcareCountry:
Hong KongIPO:
16 March 2016Website:
http://www.hutch-med.comNext earnings report:
31 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 17:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
HCM Latest News
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) has been accepted for review and granted Priority Review by the China National Medical Products Administration (“NMPA”).
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA 1 exposure — — Data supported regulatory submission in China accepted in January 2024 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31, 2024.
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online.
HUTCHMED (China) Limited ("HUTCHMED" or the "Company") announced today from Hong Kong, Shanghai, and Florham Park, N.J. (GLOBE NEWSWIRE) that:-
HUTCHMED (China) Limited will be presenting topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, along with new and updated data on investigational hematological malignancy therapies HMPL-306, HMPL-760, and tazemetostat at the upcoming European Hematology Association Hybrid Congress in Madrid, Spain.
- 1(current)
What type of business is HUTCHMED (China) Limited?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
What sector is HUTCHMED (China) Limited in?
HUTCHMED (China) Limited is in the Healthcare sector
What industry is HUTCHMED (China) Limited in?
HUTCHMED (China) Limited is in the Drug Manufacturers - Specialty & Generic industry
What country is HUTCHMED (China) Limited from?
HUTCHMED (China) Limited is headquartered in Hong Kong
When did HUTCHMED (China) Limited go public?
HUTCHMED (China) Limited initial public offering (IPO) was on 16 March 2016
What is HUTCHMED (China) Limited website?
https://www.hutch-med.com
Is HUTCHMED (China) Limited in the S&P 500?
No, HUTCHMED (China) Limited is not included in the S&P 500 index
Is HUTCHMED (China) Limited in the NASDAQ 100?
No, HUTCHMED (China) Limited is not included in the NASDAQ 100 index
Is HUTCHMED (China) Limited in the Dow Jones?
No, HUTCHMED (China) Limited is not included in the Dow Jones index
When does HUTCHMED (China) Limited report earnings?
The next expected earnings date for HUTCHMED (China) Limited is 31 July 2024